135 results on '"Trusolino, Livio"'
Search Results
2. Repurposed AT9283 triggers anti-tumoral effects by targeting MKK3 oncogenic functions in Colorectal Cancer
3. Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer
4. Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification
5. Multi-label transcriptional classification of colorectal cancer reflects tumor cell population heterogeneity
6. Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells
7. Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT)
8. Effective drug combinations in breast, colon and pancreatic cancer cells
9. Chromatin Velocity reveals epigenetic dynamics by single-cell profiling of heterochromatin and euchromatin
10. Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer
11. Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling
12. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
13. Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga
14. Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
15. Growth Factor-Dependent Activation of αvβ3 Integrin in Normal Epithelial Cells: Implications for Tumor Invasion
16. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
17. Evolving neoantigen profiles in colorectal cancers with DNA repair defects
18. Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models
19. Phosphoproteomics of patient-derived xenographs identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer.
20. Inhibition of poly(ADP-ribosyl)ation in cancer: Old and new paradigms revisited
21. MicroRNA 483‐3p overexpression unleashes invasive growth of metastatic colorectal cancer via NDRG1 downregulation and ensuing activation of the ERBB3/AKT axis.
22. CONNECTOR, fitting and clustering of longitudinal data to reveal a new risk stratification system.
23. The genomic landscape of response to EGFR blockade in colorectal cancer
24. The ROR1 pseudokinase diversifies signaling outputs in MET-addicted cancer cells
25. Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice
26. An ‘in-cell trial’ to assess the efficacy of a monovalent anti-MET antibody as monotherapy and in association with standard cytotoxics
27. MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients
28. The Met tyrosine kinase receptor in development and cancer
29. [beta]4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth
30. Cancer: the matrix is now in control
31. ANIMAL RESEARCH: Temper Italyʼs strict lab-animal law
32. A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors
33. A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth
34. Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils
35. Growth factor-dependent activation of alpha-v-beta-3 integrin in normal epithelial cells: implications for tumor invasion
36. Invasive growth: from development to metastasis
37. Integrin expression and IgA nephropathy: In vitro modulation by IgA with altered glycosylation and macromolecular IgA
38. Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition
39. Tubulointerstitial responses in the progression of glomerular diseases: Albuminuria modulates αvβ5 integrin
40. Systems analysis of protein signatures predicting cetuximab responses in KRAS, NRAS, BRAF and PIK3CA wild‐type patient‐derived xenograft models of metastatic colorectal cancer.
41. Adaptive mutability of colorectal cancers in response to targeted therapies.
42. Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer.
43. Temper Italy's strict lab-animal law
44. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.
45. Tankyrase inhibition impairs directional migration and invasion of lung cancer cells by affecting microtubule dynamics and polarity signals.
46. Stromal contribution to the colorectal cancer transcriptome.
47. IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies.
48. Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models.
49. Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies.
50. Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.